Japanese firm Shimadzu invests in ChromaCode for developing scalable PCR technology


BioSpectrum Asia:

Shimadzu will support ChromaCode’s business and contribute to the development of cancer and infectious diseases testing technologies Japan-based Shimadzu Corporation has invested in ChromaCode Inc., a US-based startup with technology to expand genetic testing, through its corporate venture capital (CVC) fund, Shimadzu Future Innovation Fund L.P. (Shimadzu FIF). This is Shimadzu FIF’s first investment.

View full article

More Articles Here